Agios Pharmaceuticals Inc (NASDAQ: AGIO) kicked off on Tuesday, down -5.51% from the previous trading day, before settling in for the closing price of $29.97. Over the past 52 weeks, AGIO has traded in a range of $23.42-$62.58.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 4.89%. While this was happening, its average annual earnings per share was recorded -163.23%. With a float of $55.76 million, this company’s outstanding shares have now reached $57.89 million.
Let’s determine the extent of company efficiency that accounts for 488 employees. In terms of profitability, gross margin is 83.22%, operating margin of -1188.86%, and the pretax margin is 1917.72%.
Agios Pharmaceuticals Inc (AGIO) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Agios Pharmaceuticals Inc is 3.72%, while institutional ownership is 105.83%. The most recent insider transaction that took place on Apr 10 ’25, was worth 194,172. In this transaction Director of this company sold 7,497 shares at a rate of $25.90, taking the stock ownership to the 149,220 shares. Before that another transaction happened on Apr 08 ’25, when Company’s Director proposed sale 7,497 for $25.90, making the entire transaction worth $194,172.
Agios Pharmaceuticals Inc (AGIO) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -163.23% per share during the next fiscal year.
Agios Pharmaceuticals Inc (NASDAQ: AGIO) Trading Performance Indicators
Take a look at Agios Pharmaceuticals Inc’s (AGIO) current performance indicators. Last quarter, stock had a quick ratio of 17.93. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 44.29.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 11.29, a number that is poised to hit -1.85 in the next quarter and is forecasted to reach -6.60 in one year’s time.
Technical Analysis of Agios Pharmaceuticals Inc (AGIO)
Looking closely at Agios Pharmaceuticals Inc (NASDAQ: AGIO), its last 5-days average volume was 0.58 million, which is a drop from its year-to-date volume of 0.71 million. As of the previous 9 days, the stock’s Stochastic %D was 52.19%. Additionally, its Average True Range was 1.62.
During the past 100 days, Agios Pharmaceuticals Inc’s (AGIO) raw stochastic average was set at 17.59%, which indicates a significant decrease from 31.06% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 40.81% in the past 14 days, which was lower than the 54.82% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $30.11, while its 200-day Moving Average is $40.12. However, in the short run, Agios Pharmaceuticals Inc’s stock first resistance to watch stands at $29.63. Second resistance stands at $30.95. The third major resistance level sits at $31.87. If the price goes on to break the first support level at $27.39, it is likely to go to the next support level at $26.47. Should the price break the second support level, the third support level stands at $25.15.
Agios Pharmaceuticals Inc (NASDAQ: AGIO) Key Stats
The company with the Market Capitalisation of 1.64 billion has total of 57,915K Shares Outstanding. Its annual sales at the moment are 36,500 K in contrast with the sum of 673,730 K annual income. Company’s last quarter sales were recorded 8,730 K and last quarter income was -89,290 K.
